Literature DB >> 23043928

Linezolid resistant Staphylococcus haemolyticus: first case report from India.

Varsha Gupta1, Shivani Garg, Ruby Jain, Sudhir Garg, Jagdish Chander.   

Abstract

Linezolid is being increasingly used in the treatment of infections with gram-positive organisms especially methicillin resistant Staphylococcal isolates. Though resistance to this antimicrobial is emerging but it is extremely rare. Here we document first case of linezolid resistant Staphylococcus haemolyticus (S.haemolyticus) from India. This organism was isolated from pus oozing from a postsurgical site in 61 year old male hailing from an adjoining state of Haryana.
Copyright © 2012 Hainan Medical College. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23043928     DOI: 10.1016/S1995-7645(12)60155-2

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  4 in total

1.  Emergence of linezolid resistance in a clinical Staphylococcus capitis isolate from Jiangsu Province of China in 2012.

Authors:  Yiling Huang; Yanling Xu; Genyan Liu; Yaning Mei; Wenying Xia; Ting Xu; Bing Gu; Shiyang Pan
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

2.  Diversity of staphylococcal cassette chromosome mec elements in nosocomial multiresistant Staphylococcus haemolyticus isolates.

Authors:  Ewa Szczuka; Magdalena Krajewska; Dagmara Lijewska; Karolina Bosacka; Adam Kaznowski
Journal:  J Appl Genet       Date:  2016-04-07       Impact factor: 3.240

3.  The Prevalence and Antimicrobial Susceptibility Pattern of Gram-Positive Pathogens: Three-Year Study at a Tertiary Care Hospital in Mumbai, India.

Authors:  Sweta Shah; Ritika Rampal; Pooja Thakkar; Sushima Poojary; Shweta Ladi
Journal:  J Lab Physicians       Date:  2021-07-02

4.  A cfr-positive clinical staphylococcal isolate from India with multiple mechanisms of linezolid-resistance.

Authors:  Vineeth Rajan; Vijay Gowdara Shankarappa Kumar; Shubha Gopal
Journal:  Indian J Med Res       Date:  2014-03       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.